Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

被引：0
|
作者：
Lu, S. [1 ]
Jian, H. [1 ]
Zhang, Y. [2 ]
Song, Z. [2 ]
Zhao, Y. [3 ]
Wang, P. [4 ]
Jiang, L. [1 ]
Gong, Y. [5 ]
Zhou, J. [6 ]
Dong, X. [7 ]
Yang, N. [8 ]
Fang, J. [9 ]
Zhuang, W. [10 ]
Cang, S. [11 ]
Ma, R. [12 ]
Shi, J. [13 ]
Wu, P. [14 ]
Lu, J. [15 ]
Xiang, Z. [16 ]
Shi, Z. [16 ]
Zhang, L. [16 ]
Wang, Y. [16 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Lung Canc Ctr, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[5] Chongqing Univ, Chongqing Canc Hosp, Canc Hosp, Chongqing, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[7] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Changsha, Peoples R China
[8] Hunan Canc Hosp, Changsha, Peoples R China
[9] Beijing Canc Hosp, Beijing, Peoples R China
[10] Fujian Prov Canc Hosp, Fuzhou, Peoples R China
[11] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[12] Liaoning Canc Hosp, Shenyang, Peoples R China
[13] Linyi Canc Hosp, Linyi, Peoples R China
[14] Gen Hosp Ningxia Med Univ, Yinchuan, Peoples R China
[15] Nantong Tumor Hosp, Nantong, Peoples R China
[16] InventisBio Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Non-small cell lung cancer; KRAS G12C mutation; Small molecular inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA03.07
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [1] D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
    Kondo, S.
    Yan, D.
    Ganju, V.
    Richardson, G.
    Hou, X.
    Shan, J.
    Liu, X.
    Zhang, Y.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Wang, Y.
    Zhang, L.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S898 - S899
  • [2] Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
    Xu, R-H.
    Xu, Y.
    Yan, D.
    Munster, P.
    Ruan, D.
    Deng, Y.
    Pan, H.
    Underhill, C. R.
    Richardson, G.
    Nordman, I.
    Lee, K-W.
    Wei, S.
    Li, X.
    Shan, J.
    Han, G.
    Henderson, S.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S410 - S411
  • [3] Real World Efficacy and Safety of Sotorasib in US Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
    Zhou, K. I.
    Lin, C.
    Tseng, C. -L.
    Ramnath, N.
    Dowell, J. E.
    Kelley, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S337 - S338
  • [4] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
    Pellini, B.
    Ganesan, V.
    Wan, F.
    Sankararaman, S.
    Manyanont, S.
    Akhave, N.
    Baggstrom, M.
    Ward, J.
    Waqar, S.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
  • [5] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [6] Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study
    Song, Zhengbo
    Li, XingYa
    Lin, Rongbo
    Yuan, Yuan
    Shi, Huaqiu
    Liu, Ying
    Luo, Yongzhong
    Lv, Tangfeng
    Zhang, Yiping
    Zhu, Yinxin
    Wang, Zaiqi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study
    Ruan, Dan-yun
    Lee, Myung Ah
    Deng, Yanhong
    Lee, Keun-Wook
    Millward, Michael
    Grewal, Jaspreet Singh
    Gadgeel, Shirish M.
    Sanborn, Rachel E.
    Hou, Xinfang
    Wei, Shaozhong
    Huh, Seok Jae
    Liu, Fu-Rong
    Xie, Xiaoxi
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Richardson, Gary Edward
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [9] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Alessandro Di Federico
    Ilaria Ricciotti
    Valentina Favorito
    Sandra Vietti Michelina
    Pietro Scaparone
    Giulio Metro
    Andrea De Giglio
    Federica Pecci
    Giuseppe Lamberti
    Chiara Ambrogio
    Biagio Ricciuti
    Current Oncology Reports, 2023, 25 : 1017 - 1029
  • [10] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Di Federico, Alessandro
    Ricciotti, Ilaria
    Favorito, Valentina
    Michelina, Sandra Vietti
    Scaparone, Pietro
    Metro, Giulio
    De Giglio, Andrea
    Pecci, Federica
    Lamberti, Giuseppe
    Ambrogio, Chiara
    Ricciuti, Biagio
    CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
12345